Dose Selection in Phase I Studies: Why We Should Always Go for the Most Effective
Author:
Affiliation:
1. Melbourne Oncology Group, Cabrini Health, Malvern; and Monash University, Melbourne, Australia
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2008.17.6719
Reference21 articles.
1. Dose Selection in Phase I Studies: Why We Should Always Go for the Top
2. A Positive Step Forward, but More Needed to Maximize Cost Benefits of New-Generation Cancer Therapies
3. Paclitaxel plus Bevacizumab for Metastatic Breast Cancer
4. Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
5. Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Health-related quality of life as an endpoint in oncology phase I trials: a systematic review;BMC Cancer;2019-04-16
2. A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424;British Journal of Cancer;2018-02-13
3. Determinants of the recommended phase 2 dose of molecular targeted agents;Cancer;2017-02-09
4. Strategies to Help Oncologists Deliver High-Quality Care;Journal of Clinical Oncology;2014-06-20
5. A Snapshot of Challenges and Solutions in Cancer Drug Development and Therapy;Clinical Pharmacology & Therapeutics;2014-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3